Page last updated: 2024-11-05

ici 204,219 and Lung Diseases, Obstructive

ici 204,219 has been researched along with Lung Diseases, Obstructive in 2 studies

zafirlukast: a leukotriene D4 receptor antagonist

Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.

Research Excerpts

ExcerptRelevanceReference
"The present study was designed to evaluate the bronchodilating role of zafirlukast, a CysLT(1)receptor antagonist, at the standard dosage currently recommended in the marketing of this agent in smokers with COPD."2.69Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. ( Allegra, L; Boveri, B; Carlucci, P; Cazzola, M; Centanni, S; DiMarco, F; Santus, P, 2000)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nathan, RA1
Bernstein, JA1
Bielory, L1
Bonuccelli, CM1
Calhoun, WJ1
Galant, SP1
Hanby, LA1
Kemp, JP1
Kylstra, JW1
Nayak, AS1
O'Connor, JP1
Schwartz, HJ1
Southern, DL1
Spector, SL1
Williams, PV1
Cazzola, M1
Boveri, B1
Carlucci, P1
Santus, P1
DiMarco, F1
Centanni, S1
Allegra, L1

Trials

2 trials available for ici 204,219 and Lung Diseases, Obstructive

ArticleYear
Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.
    The Journal of allergy and clinical immunology, 1998, Volume: 102, Issue:6 Pt 1

    Topics: Adolescent; Adult; Aged; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Humans;

1998
Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist.
    Pulmonary pharmacology & therapeutics, 2000, Volume: 13, Issue:6

    Topics: Aged; Albuterol; Anti-Asthmatic Agents; Area Under Curve; Bronchodilator Agents; Cross-Over Studies;

2000